Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism

被引:182
作者
Maurer, BJ
Melton, L
Billups, C
Cabot, MC
Reynolds, CP
机构
[1] Childrens Hosp, Div Hematol Oncol, Los Angeles, CA 90027 USA
[2] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA USA
[3] St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2000年 / 92卷 / 23期
关键词
D O I
10.1093/jnci/92.23.1897
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways. Our goal was to determine if several molecules that inhibit enzymes involved in ceramide metabolism-L-threo-dihydrosphingosine (safingol), d,l-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (PPMP), and tamoxifen-enhanced 4-HPR-mediated cytotoxicity and/or affected ceramide levels. Methods: Cellular lipids were quantified by radiolabeling and thin-layer chromatography. Cytotoxicity and cytotoxic synergy (expressed as combination index, where combination index <1 indicates synergy and >1 indicates antagonism) were measured in cultured cancer cell lines with the use of a fluorescence-based assay of cen viability employing digital imaging microscopy, Statistical tests were two-sided. Results: 4-HPR increased ceramide levels by de nova synthesis, Safingol (1-4 muM) was incorporated into a stereochemical variant of ceramide and synergized with a 3:1 molar ratio of 4-HPR (3-12 muM), to produce a 100-fold to 10 000-fold (2 to 4 logs) increase in cytotoxicity relative to 4-HPR alone in neuroblastoma (combination index <0.1), lung (combination index <0.1-0.2), melanoma (combination index <0.1-0.2), prostate (combination index <0.1-1.0), colon (combination index 0.1-0.3), breast (combination index = 0.1-0.5), and pancreas (combination index = 0.2) cell lines, including p53 mutant and alkylator-resistant cell fines, The 4-HPR and safingol combination was cytotoxic in low-oxygen conditions and was minimally toxic to normal fibroblasts and bone marrow myeloid progenitor cells. Addition of agents that retard ceramide glucosylation and/or acylation, such as PPMP or tamoxifen, to 4-HPR or to the combination of 4-HPR and safingol further increased cytotoxicity to tumor cells, Conclusions: Combinations of 4-HPR and modulators of ceramide metabolism may form the basis for a novel chemotherapy that is functional under hypoxic conditions (e.g., such as those within tumors) and is p53 independent and caspase independent.
引用
收藏
页码:1897 / 1909
页数:13
相关论文
共 80 条
[1]  
ABE A, 1995, J LIPID RES, V36, P611
[2]   Purification and characterization of 1-O-acylceramide synthase, a novel phospholipase A2 with transacylase activity [J].
Abe, A ;
Shayman, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) :8467-8474
[3]  
ANDERSON CP, 2000, IN PRESS J PEDIAT HE
[4]  
Bagniewski P. G., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P92
[5]  
BERMAN E, 1995, LEUKEMIA, V9, P1631
[6]   Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta [J].
Berra, E ;
DiazMeco, MT ;
Lozano, J ;
Frutos, S ;
Municio, MM ;
Sanchez, P ;
Sanz, L ;
Moscat, J .
EMBO JOURNAL, 1995, 14 (24) :6157-6163
[7]   Tamoxifen retards glycosphingolipid metabolism in human cancer cells [J].
Cabot, MC ;
Giuliano, AE ;
Volner, A ;
Han, TY .
FEBS LETTERS, 1996, 394 (02) :129-131
[8]   Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A - Activation is stereospecific and regulated by phosphatidic acid [J].
Chalfant, CE ;
Kishikawa, K ;
Mumby, MC ;
Kamibayashi, C ;
Bielawska, A ;
Hannun, YA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (29) :20313-20317
[9]   c-jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide [J].
Chen, YR ;
Zhou, GS ;
Tan, TH .
MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1271-1279
[10]   Drug combinations: From laboratory to practice [J].
Chou, TC .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (01) :6-8